GEDiCube is an artificial intelligence and machine learning platform that combines differential molecular capabilities with multi-omic analysis.
NVIDIA Inception intends to deploy GEDiCube’s platform, powered by its accelerated infrastructure leveraging the Medical Imaging Open Network for Artificial Intelligence (MONAI), creating the potential to revolutionise the early detection of pancreatic cancer.
This multi-modal approach will be used for the first time in an upcoming clinical trial, where MONAI will be used to detect and build a predictive model based on tumour size combined with the multi-omic platform based on tumour type.
According to both companies, this approach by GEDiCube will help provide important information for fighting cancers, like pancreatic cancer, that nearly always present in late stages and have predominately poor outcomes. In fact, many patients die within months of diagnosis.
Combining and analysing as much data as possible using artificial intelligence will potentially increase the efficiency of the clinical trial and create more clinical trial opportunities for GEDiCube.
Craig Rhodes, CEO of GEDiCube, said: “This is a natural fit for GEDiCube that will help us in our mission to detect cancer at its earliest stage.”
“NVIDIA’s advanced medical imaging capabilities with GEDiCube’s existing multi-omic AI system will help create an algorithm that pulls from both the imaging and omic modals. This will help our scientists understand the radiology and pathology imaging data alongside multi-omic data, thus enabling a better analysis of cancer.”